"Patient groups and Eisai are upbeat but many doctors remain unconvinced and healthcare providers are restricting reimbursement. #Lecanemab, for all its landmark status, may end up representing a triumph of hope over evidence."

#Alzheimer #AlzheimersDisease

https://www.ft.com/content/34031d7e-909f-49c1-9550-cfcf36194fa2

zum #Alzheimer-Medikament #Lecanemab 👇 ⚡️⚡️

https://citizen.org/lecanemab-letter/

Wir berichteten schon Mitte 2021:
https://bukopharma.de/de/publikationen/pharma-brief-archiv/172-2021-artikel/522-usa-zulassung-ohne-evidenz

This commentary blog "In the pipeline" published on the Science .org homepage has a very unusual format. Fun to read, not the boring science writing you normally get. But what is this? Just a Pharma guy (Derek Lowe) with an opinion, independent of Science Magazine editors?

Very pragmatic take on the new #Alzheimer drug #Lecanemab - I like it.

https://www.science.org/content/blog-post/lecanemab-and-alzheimer-s-more-data

Despite great excitement that in the phase 3 #Alzheimer trial #lecanemab reduced cognitive decline, this sounds far less encouraging for patients than initially communicated...

Not to belittle the results, any advancement and any successful phase 3 trial in this devastating disease is a HUGE success for science. but to have a real patient impact it will take more science, more trials, new ideas.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02480-1/fulltext

Alzheimer's drug lecanemab hailed as momentous breakthrough

https://www.bbc.com/news/health-63749586
#Alzheimer #AlzheimersDisease #Dementia #Lecanemab #Drugs #Medicine #Healthcare